GlassScriptPhysician profile
Michael S Urban
NPI 1831105485
$6,995.30
in general payments reported to CMS, 2019-2025
32 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $921 · 2021: $849 · 2022: $862 · 2023: $881 · 2024: $1,224 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,227.59 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,549.28 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Janssen Biotech, INC. | $941.52 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $667.69 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $631.93 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $386.20 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $377.26 | 2019-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $279.03 | 2019-2025 | Clenpiq |
| Redhill Biopharma INC. | $266.04 | 2020-2022 | |
| Celgene Corporation | $196.28 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $169.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $158.32 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $154.16 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $138.92 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $132.10 | 2020-2024 | Dificid |
| Concordia Pharmaceuticals INC. | $120.87 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $114.49 | 2024-2025 | Zenpep |
| Intercept Pharmaceuticals, INC. | $85.73 | 2020-2021 | |
| Ardelyx, INC. | $80.59 | 2022-2025 | Ibsrela |
| Romark Laboratories, Lc | $75.32 | 2019-2020 | |
| Genzyme Corporation | $71.90 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $54.35 | 2025 | Dupixent |
| Celltrion USA INC. | $52.77 | 2024 | Vegzelma |
| Lilly USA, LLC | $52.65 | 2024-2025 | Omvoh |
| Exact Sciences Corporation | $49.30 | 2023-2025 | Cologuard Collection Kit |
| Braintree Laboratories, INC. | $44.07 | 2019-2024 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $37.55 | 2023 | |
| Novo Nordisk INC | $26.76 | 2025 | Wegovy |
| Medtronic, INC. | $19.68 | 2025 | Pillcam |
| Amgen INC. | $19.26 | 2023 | Avsola, Amjevita |
| Evoke Pharma, INC. | $17.93 | 2024 | |
| Vivus LLC | $15.53 | 2021 | |
| Micro-Tech Endoscopy USA, INC. | $8.25 | 2024 | Cold Snares |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Urban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.